Navigation Links
SonaCare Medical Partners with University College London to Create Center of Excellence for HIFU Surgical Ablation Technology
Date:5/2/2013

CHARLOTTE, N.C., May 2, 2013 /PRNewswire/ -- SonaCare Medical, a global leader in minimally invasive HIFU technologies, announced today that it has partnered with University College London (UCL) to create a HIFU Center of Excellence. The Center of Excellence will provide physician training and proctoring along with clinical studies, patient satisfaction research and advanced technology development associated with two innovative HIFU systems: the Sonatherm® laparoscopic HIFU surgical ablation system and the Sonablate® 500 transrectal HIFU surgical ablation system.

According to Mark Emberton , MD, Director of the Division of Surgery and Interventional Science, University College London, "Our collaboration with SonaCare Medical's innovative technology provides a great platform for us to help expand the use of HIFU in a responsible and effective way. Tissue preserving strategies have been used successfully in other solid organ cancers, such as kidney cancer with great results. Published results from our practice continue to demonstrate that focal therapy delivers good cancer control along with a significant reduction in treatment side effects, which suggests a new option in a spectrum of prostate cancer care that, based on risk profile, can effectively balance clinical benefits and quality of life.

"The highly precise Sonablate 500 HIFU transrectal system has already proven an effective way to transition from treating the entire prostate to treating only the known prostate cancer and the addition of the Sonatherm® laparoscopic system allows us to offer an important new minimally invasive option for certain tumors," added Dr. Emberton.

UCL researchers presented multiple abstracts highlighting the ability of HIFU to balance disease control and quality of life at the recent European Association of Urology (EAU) Congress, including ongoing results from the UK Focal Therapy Study published in Lancet Oncology (DOI:10.1016/S1470-2045(12)70121-3). In this study "Focal Therapy Targeted to the Index Lesion in Multifocal Prostate Cancer: a Prospective Development Study," UCL researchers evaluated the outcomes in men with multi-focal disease in which patients received focal HIFU therapy delivered to clinically significant cancer lesions using the Sonablate 500, developed by SonaCare Medical. Results showed that no biopsy evidence of cancer was identified in the treated regions in 60 percent of men and 83 percent were free of clinically significant cancer. The trifecta rate, which was defined as pad-free leak-free continence, erections sufficient for intercourse, and absence of clinically significant disease at 12 months, was achieved by 87 percent of men who completed the study.   

"Europe has a long history of using HIFU to treat a range of clinical conditions.  SonaCare Medical is extending the reach of HIFU for multiple urologic indications, including laparoscopic ablation of the kidney, transrectal ablation of the prostate and transurethral ablation of the bladder," said Mark Carol , M.D., Chief Development Officer for SonaCare Medical.  "We look forward to working with UCL to validate these approaches and to introduce them into the European markets."  

UCL previously reported on the use of HIFU to treat the entire half of the prostate where cancer was found. That study also showed similar reduction in side-effects and encouraging early cancer control. In the focal HIFU study, researchers wanted to evaluate whether damage to healthy tissue could be further reduced by treating only the specific cancer sites in one or both sides. Results suggest that after focal therapy men have a 9 in 10 chance of achieving excellent clinical results at 12 months with no urine leakage, good erections and no imaging evidence of disease.

"SonaCare Medical has partnered with UCL for many years to provide physician training and to support UCL's ground-breaking research in the field of HIFU.  We have tremendous respect for the clinical and academic leadership Dr. Mark Emberton and his team at UCL has brought to the field of HIFU and the diagnosis and minimally invasive treatment techniques for prostate cancer. We are proud to formalize this long-term relationship through the creation of this important HIFU Center of Excellence designed to support further clinical and technical advances," said Michael Klein , CEO for SonaCare Medical.

About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S.

SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C. Additional information may be found at www.SonaCareMedical.com.


'/>"/>
SOURCE SonaCare Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. US HIFU Announces Name Change To SonaCare Medical
2. SonaCare Medical to Introduce Two New HIFU Products at the European Association of Urology (EAU) Congress
3. SonaCare Medical Successfully Launches New Products at European Association of Urology (EAU)
4. SonaCare Medical to Integrate SmartTarget Image Registration and Fusion Software from University College London into Industry Leading Prostate HIFU System
5. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
6. Medical Device Developers - Network at BIOMEDevice Boston Next Week
7. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
10. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb. 24, 2017 Research ... Health Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 23.8% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow ... approximately $2.9 billion by 2025. This industry report analyzes ... as well as regional levels presented in the research scope. The study ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... , ... IndustryArchive.Org . is announcing a new way for B2B Sellers ... only pay for B.A.N.T. quality sales leads based on the Sellers decision to purchase ... reality that B2B buyers are controlling the sales process via the Internet and that ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the 10th ... Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on how ... management. , ODH will also have an exhibit booth where attendees may speak to ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide ... with a specific LRRK2 mutation, according to a study released today at the ... evidence of a link between pesticides and incidence of sporadic PD through occupational ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release ... show in Cannes (France), XO Private has initiated a second print-run of its lavish ... almost a metre across when open, weighs in at more than six kilos, retails ...
Breaking Medicine News(10 mins):